Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

622
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
622
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

540
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
540
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

617
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
617
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

645
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
645
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

493
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
493

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microaffirmations, counterspaces, and mental health: Supporting Black male students at Predominantly White Institutions.

Cultural diversity & ethnic minority psychology·2026
Same author

Cell death regulation: A novel way of natural products to treat myocardial hypertrophy.

Ageing research reviews·2026
Same author

Residual Inflammatory Risk in Atherosclerotic Cardiovascular Disease: Are We Ready for Targeted Therapies?

The Canadian journal of cardiology·2026
Same author

Pathological disruption of CELF2 shuttling causes neuronal hyperactivity, learning deficits, and seizures.

The Journal of clinical investigation·2026
Same author

CRISPR/Cas9-mediated disruption of Cmpks1 reveals its role as a key regulator of carotenoid biosynthesis and metabolic adaptation in Cordyceps militaris.

International journal of biological macromolecules·2026
Same author

OmniEdit: A unified CRISPR/Cas9 platform for precise genome engineering and strain optimization of the <i>Cordyceps militaris</i> cell factory.

Synthetic and systems biotechnology·2026

Related Experiment Video

Updated: Feb 20, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K

Abnormal Lipid Signaling Characterizes Diastolic Dysfunction in Pediatric Cardiomyopathy.

Andrei L Turinsky1, Nour Hanafi1, Abdelrahman Said2

  • 1Centre for Computational Medicine, Hospital for Sick Children, Toronto, Ontario, Canada.

JACC. Basic to Translational Science
|February 18, 2026
PubMed
Summary
This summary is machine-generated.

Pediatric cardiomyopathy causes diastolic heart failure through unclear mechanisms. Abnormal lipid signaling and accumulation in heart muscle cells are key, offering semaglutide as a potential treatment for childhood heart conditions.

Keywords:
RNA sequencingcardiomyopathydiastolic dysfunctioniPSC cardiomyocyteslipidomemultiomics

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K
Quantification of Global Diastolic Function by Kinematic Modeling-based Analysis of Transmitral Flow via the Parametrized Diastolic Filling Formalism
11:04

Quantification of Global Diastolic Function by Kinematic Modeling-based Analysis of Transmitral Flow via the Parametrized Diastolic Filling Formalism

Published on: September 1, 2014

11.6K

Related Experiment Videos

Last Updated: Feb 20, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K
Quantification of Global Diastolic Function by Kinematic Modeling-based Analysis of Transmitral Flow via the Parametrized Diastolic Filling Formalism
11:04

Quantification of Global Diastolic Function by Kinematic Modeling-based Analysis of Transmitral Flow via the Parametrized Diastolic Filling Formalism

Published on: September 1, 2014

11.6K

Area of Science:

  • Cardiology
  • Metabolomics
  • Molecular Biology

Background:

  • Pediatric cardiomyopathy is a significant cause of diastolic heart failure.
  • The underlying molecular mechanisms of this condition, particularly diastolic dysfunction, are not well understood.
  • Identifying specific molecular signatures is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the molecular mechanisms of diastolic dysfunction in pediatric cardiomyopathy.
  • To identify a distinct metabolic and transcriptomic signature associated with diastolic dysfunction.
  • To explore potential therapeutic targets for childhood cardiomyopathy.

Main Methods:

  • Global myocardial transcriptomic and blood lipidomic profiling were performed.
  • A machine learning model was developed using identified gene markers to classify diastolic dysfunction.
  • Induced pluripotent stem cell-derived cardiomyocytes from patients were analyzed for lipid accumulation and mitochondrial function.
  • The efficacy of semaglutide in rescuing cellular dysfunction was assessed.

Main Results:

  • A unique metabolic signature characterized by dysregulated lipid signaling was identified in diastolic dysfunction.
  • Excess saturated lipids and impaired lipid oxidation correlated with myocardial gene expression changes.
  • The machine learning model accurately classified diastolic dysfunction across different cardiomyopathy subtypes.
  • Patient-derived cardiomyocytes showed lipid accumulation and mitochondrial dysfunction, which were ameliorated by semaglutide treatment.

Conclusions:

  • Diastolic dysfunction in pediatric cardiomyopathy is associated with a distinct molecular phenotype involving abnormal lipid signaling.
  • Impaired lipid metabolism and mitochondrial dysfunction are key features of this condition.
  • Targeting abnormal lipid signaling, potentially with agents like semaglutide, represents a promising therapeutic strategy for childhood cardiomyopathy.